Hoffmann-la Roche Inc.

Purdue Pharma L.p.

Roche Palo Alto LLC

L'oreal

Stephen Matthew Lynch

Michael Soth

Laykea Tafesse

Johannes Cornelius Hermann

Yan Lou

Matthew C Lucas

Robert James Weikert

Timothy D Owens

Patricia Brieva

Ryan Craig Schoenfeld

Rama K Kondru

Robert Than Hendricks

Maggie Su

Jiangchao Yao

Jae Hyun Park

Ann Marie Madera

Clara Jeou Jen Lin

Pravin Iyer

Madeline Jane Sverdlove

Kerem Erol Ozboya

Werner Neidhart

Matthew Michael Hamilton

Ce Wang

Jean-Marc Plancher

Robert J Greenhouse

Javier De Vicente Fidalgo

Tanja Schulz-Gasch

Achyutharao Sidduri

Kin-Chun Thomas Luk

Peter Michael Wovkulich

Alam Jahangir

Angelike Galdi

Allen John Lovey

Shaoqing Chen

Keshab Sarma

Hongju Li

Terrence Joseph Connolly

Joshua Jahmil Kennedy-Smith

Hanbiao Yang

Saul Jaime-Figueroa

Eric Roy Humphreys

Fernando Padilla

Xiaohu Zhang

Karin Ann Stein

Lubica Raptova

Robert Patrick Farrell

Counde O'yang

Calvin Yee

Ashleigh Nichole Murtaugh-Frey

Alison Nicole Taylor

A skin care composition includes a gel stabilized emulsion comprising a combination of actives that include azelaic acid, at least one hydroquinone derivative, and niacinamide, at least one anionic polymer thickener, and at least one fatty compound. The provides a hydrating formula that is comfortable for the wearer and is oil free, without appearing shiny or greasy on the skin, and includes actives to treat the appearance of dark spots and inflammatory lesions, including acne, for all skin types. The skin care composition is free or essentially free of monoalcohols, silicones, silicone oils, and oils other than fatty compounds that comprise emollient esters, hydrogenated polyisobutene, and squalane.

Gel stabilized O/W emulsion with alpha-arbutin and azelaic acid dispersion

The Invention provides indole derivatives of Formula I: and pharmaceutically acceptable salts and solvates thereof, wherein R, R, A, X, Y, Z, and Ware defined as set forth in the specification. The Invention also provides the use of compounds of Formula I and the pharmaceutically acceptable salts and solvates thereof to treat pain. In certain embodiments, the Compounds of the Invention are effective in treating a disorder responsive to blockade of one or more sodium channels.

Indole derivatives and use thereof

The present disclosure relates to stable cosmetic compositions that include high levels of free glycolic acid. The cosmetic compositions typically include: glycolic acid and/or a salt thereof; at least one non-silicone fatty compound; at least one emulsifier; at least one water-soluble solvent; at least one silicone; and water. The cosmetic compositions are in the form of an emulsion, in particular, a water-in-oil emulsion, and typically have a low pH of below 7. Also, the cosmetic compositions have high amount of free glycolic acid, for example, at least 6 wt. % of free glycolic acid, based on the total weight of the cosmetic composition. The cosmetic compositions are particularly useful for improving the appearance of skin. Accordingly, the instant disclosure relates to methods of treating skin, for example, improving the appearance of skin using the cosmetic compositions.

Cosmetic composition comprising glycolic acid and methods of use

Cosmetic compositions comprising high amount ofExtract, relatively high amounts of skin active ingredients chosen from salicylic acid, ascorbic acid, a cinnamic acid derivative, or a mixture thereof; c) one or more surfactants; d) from about 3 to about 15 wt. % of Propylene Glycol; e) from about 5 to about 18 wt. % of Dipropylene Glycol; and f) water; and wherein the composition has a pH not higher than about 5.

Serums for reducing lipid peroxidation

The present disclosure provides dibenzazepine derivatives having Formula I or I(A): and the pharmaceutically acceptable salts and solvates thereof, wherein R, R, R, V, V, Z, Z, Z, and G are defined as set forth in the specification. The present disclosure is also directed to the use of the compounds of Formula I or I(A), and the pharmaceutically acceptable salts or solvates thereof, to treat a disorder responsive to the blockade of one or more sodium channels. In one embodiment, the compounds of the present disclosure are useful for treating pain.

Dibenzazepine derivatives and use thereof

The present disclosure provides pyridines and pyrimidines of Formula I and pharmaceutically acceptable salts and solvates thereof: wherein A, G, W, W, W, and Rare defined as set forth in the specification. The present disclosure also provides uses of the compounds of Formula I and pharmaceutically acceptable salts and solvates thereof. In certain embodiments, Compounds of the present disclosure are useful for treating pain. In another embodiment, Compounds of the present disclosure are useful for treating a disorder responsive to blockade of sodium channels, or alleviating symptoms of the disorder. 

Pyridines and pyrimidines and use thereof

The invention is concerned with the compounds of formula (I) and pharmaceutically acceptable salts thereof. In addition, the present invention relates to methods of manufacturing and using the compounds of formula I as well as pharmaceutical compositions containing such compounds. The compounds of formula I are LMP7 inhibitors and may be useful in treating associated inflammatory diseases and disorders such as, for example, rheumatoid arthritis, lupus and irritable bowel disease. 

Substituted triazole boronic acid compounds

The present invention relates to the use of novel pyrrolopyrazine derivatives of Formula I, wherein the variables are defined as described herein, which inhibit JAK and SYK and are useful for the treatment of auto-immune and inflammatory diseases.

Pyrrolopyrazine kinase inhibitors

The present invention relates to the use of novel pyrrolopyrazine derivatives of Formula I, wherein the variables n, p, q, Q, X, X' and Y are defined as described herein, which inhibit JAK and SYK and are useful for the treatment of auto-immune and inflammatory diseases.

Heteroaryl pyrrolidinyl and piperidinyl ketone derivatives and uses thereof

The present invention relates to the use of novel pyrrolopyrazine derivatives of Formula I, wherein the variables Q, R, R, and Y are defined as described herein, which inhibit JAK and SYK and are useful for the treatment of auto-immune and inflammatory diseases.

The present invention relates to the use of novel pyrrolopyrazine derivatives of Formula I, wherein the variables Q and Rand Rare defined as described herein, which inhibit JAK and SYK and are useful for the treatment of auto-immune and inflammatory diseases.

The present invention relates to the use of novel macrocyclic compounds of Formula I, wherein the variables Q, Q, Q, Q, and Qare defined as described herein, which inhibit JAK and are useful for the treatment of auto-immune and inflammatory diseases.

Macrocyclic inhibitors of JAK

Growing community of inventors

Westfield, NJ, United States of America

Stephen Matthew Lynch